Search clinical trials for: Untreated High Risk Follicular Lymphoma

Total 41848 results

M.D. Anderson Cancer Center
Cephalon

Terminated

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Follicular Lymphoma

United States
European Organisation for Research and Treatment...

Completed

Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

Cancer

Belgium, Netherlands, Italy, Hungary, France, Spain, Germany, Israel, Czech Republic, United Arab Emirates, Sweden, Greece, Turkey, Portugal, Slovakia
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Cancer
Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
M.D. Anderson Cancer Center
Kite, A Gilead Company; Acerta Pharma, LLC

Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Masonic Cancer Center, University of Minnesota

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Lymphoma | Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Spain, France, Netherlands, Poland, Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Loss of Chromosome 17p

United States
Ludwig-Maximilians - University of Munich
Bayer; Roche Pharma AG

Active, not recruiting

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

Follicular Lymphoma

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditions

United States
Sumithira Vasu

Completed

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
University of Arizona

Active, not recruiting

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Lymphoma, Follicular | Myelodysplastic Syndromes | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Marginal Zone Lymphoma | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Lymphoma, Hodgkin | Gray Zone Lymphoma | Lymphoma,Non-Hodgkin | Large Cell Lymphoma | High Risk Undifferentiated...

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Lymphoma

United States
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
M.D. Anderson Cancer Center
GlaxoSmithKline

Completed

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia

United States
Atara Biotherapeutics
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Completed

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Completed

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Follicular Lymphoma | Myeloid Leukemia | Polycythemia Vera | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Refractory... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.

Completed

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Biogen

Completed

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Lymphoma

Switzerland, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom, France, Czechia
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Lymphoma

United States
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

High Risk Acute Myeloid Leukemia

United States, Canada
Lymphoma Study Association
Amgen

Completed

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Untreated CD20-positive Large B-cell Lymphoma

France
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
Ohio State University Comprehensive Cancer Center

Completed

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Lymphoma | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm

United States
Masonic Cancer Center, University of Minnesota

Terminated

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
University of Louisville
Penn State University

Completed

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Cancer

United States
Fondazione Italiana Linfomi ONLUS

Terminated

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (FIL-GALILEO)

Lymphoma, B-Cell

Italy
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Withdrawn

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Leukemia
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia

Leukemia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia

Leukemia
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Unknown

A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients

High Risk | T-cell Lymphoma Adults | Previously Untreated

China
National Cancer Institute (NCI)

Completed

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Withdrawn

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, B-Cell, Marginal Zone | Lymphoma, Low-Grade | Lymphoma, Intermediate-Grade
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Lymphoma | Small Intestine Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Institute of Allergy and Infectious...

Completed

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonneoplastic Condition | Myelodysplastic/Myeloproliferative Neoplasms

Search clinical trials for: Untreated High Risk Follicular Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations